Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Study sponsor: Travere Therapeutics, Inc. · TVTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-03-12Estimated
Enrollment · participants67Estimated
Source updated2026-05-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.